Articles tagged with B Cell Lymphoma
A new analysis shows that 42% of treated patients were functionally cured, marking a game-changer for an incurable disease. Recurrence rates declined drastically over time, from 6.8% in the first five years to 0.6% between 15 and 20 years.
Researchers analyzed 15-year data from a clinical trial, finding that 70% of patients remained alive and 42% were considered cured after treatment. Cure modeling estimated the overall cure rate at 42% of treated patients.
A team of researchers at VCU Massey Comprehensive Cancer Center has discovered an innovative way to use a drug already approved in treating irregular heartbeat to selectively target specific functions of enzymes in lymphoma, effectively killing cancer cells and reducing tumor growth with little to no toxicity. The study found that RBF4...
A new study reveals that mature B cells temporarily gain plasticity during the antibody-making process, which could explain how many lymphomas develop from mature B cells. Researchers discovered that this epigenetic change is tightly regulated and can be hijacked by specific mutations to promote lymphomagenesis.
A virtual diet and exercise program has been shown to reduce treatment side effects and increase treatment retention, according to a Sylvester study presented at ASH 2025. Lifestyle interventions can also help patients with blood cancers such as MDS and large B-cell lymphoma receive more effective and less toxic treatments.
Researchers from the University of Miami Miller School of Medicine and Sylvester Comprehensive Cancer Center will present their work on various hematological conditions at ASH 2025. These posters highlight recent findings in fields such as von Willebrand disease, multiple myeloma, and acute myeloid leukemia.
An international study has shown that BrECADD preserves fertility significantly better than eBEACOPP without worsening recovery chances. After treatment, 95% of women and 86% of men had normal hormone levels, enabling more pregnancies and births.
The study reveals three new subsets of follicular T cells that increase in follicular lymphoma, each with distinct gene expression and spatial distribution patterns. These T-cell subsets serve as a strong predictor of patient prognosis, enhancing treatment approaches for the disease.
Researchers identified three subgroups of patients with large B-cell lymphoma who have different levels of benefit from CD19 CAR T cell therapy. The study provides new insights to guide physicians toward the best clinical pathways for patients based on tumor biology.
Researchers at MD Anderson Cancer Center have made breakthroughs in understanding pancreatic cancer metastases and identifying potential biomarkers for treatment-resistant pancreatic cancer. A comprehensive spatial map provides insights into lineage shifts in cancer cells transitioning from primary tumors to organ-specific metastases.
A new strategy for treating B-cell lymphoma has shown promising results with a next-generation CAR T cell therapy that incorporates IL18. The treatment achieved high remission rates of 81% and complete remission in 52%, with some patients experiencing durable responses lasting two years or more.
A recent study found significant elevated expression of AID enzyme in B cells during Plasmodium falciparum malaria, linking the parasite to the development of Burkitt lymphoma. Elevated AID levels were also observed in Kenyan children with uncomplicated malaria.
A new type of cell-based immunotherapy has been shown to be safe and effective in treating B-cell lymphomas, with early data suggesting it could offer a less toxic alternative to CAR-T cell therapies. The approach uses off-the-shelf CAR-natural killer cells that can target cancer cells in two different ways.
Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL) is a rare subtype of Hodgkin lymphoma characterized by a nodular growth pattern and distinctive lymphocyte-predominant cells. The disease typically presents with localized lymphadenopathy and an indolent course, but can transform into diffuse large B-cell lymphoma in approximately...
Researchers discovered that variations in macrophages, ancient immune cells, are linked to patients' recovery and survival in diffuse large B-cell lymphoma. The study found subsets of macrophages associated with relapse after chemotherapy, predicting disease progression and potential new therapeutic approaches.
Researchers have identified an inflammatory protein profile associated with poor survival in aggressive B-cell lymphoma patients. Protein profiles from blood samples can help classify subtypes of the disease and monitor patient response to treatment.
Researchers developed novel therapeutic bispecific antibodies targeting IgM and B-cell surface antigens, which directly inhibited cell proliferation via cell-cycle arrest and apoptosis in vitro. These findings suggest that anti-IgM/B-cell surface antigen-binding specific antibodies are promising therapeutic agents for B-cell malignancies.
Researchers identified a group of proteins that help cancer cells maintain genetic stability and avoid immune system detection. By depleting these proteins, they triggered an inflammatory response and made the cancer cells visible to the immune system.
Researchers identified key characteristics associated with improved CAR T outcomes in large B cell lymphoma, including a B-cell gene expression signature and high CD19 protein expression. Patients who received axicabtagene ciloleucel had better event-free survival compared to those receiving standard therapy.
A study found that patients with refractory large B-cell lymphoma who received bendamustine before CAR T-cell therapy had a shorter progression-free survival and overall response rate compared to those who did not receive bendamustine. The use of bendamustine should be avoided in these patients when possible.
A new study by Dana-Farber Cancer Institute researchers found that CAR-T therapy offers superior event-free and overall survival compared to salvage chemoimmunotherapy. However, the current list price of $400,000 per infusion makes cost-effectiveness a concern.
A Phase III trial found that axicabtagene ciloleucel (axi-cel) significantly improved overall survival and progression-free survival in patients with early relapsed or refractory large B-cell lymphoma, compared to standard therapy. The estimated four-year survival rate was 54.6% with axi-cel.
Researchers at Georgia Institute of Technology developed a synthetic tumor model to understand the impact of microenvironment on targeted therapies for Activated B Cell-like Diffuse Large B cell lymphoma. The model showed promise in demonstrating how combining therapeutics can overcome tumor resistance to inhibitors.
Researchers report an updated analysis from a phase I study of mivavotinib, a spleen tyrosine kinase inhibitor, in patients with relapsed/refractory B-cell lymphoma. The study showed a 45% overall response rate and median duration of response of 28.1 months in the overall cohort.
Researchers found that female lymphoma patients who received afternoon chemotherapy had a 12.5 times reduced mortality rate and a 2.8 times decreased cancer recurrence rate compared to morning treatment. This is due to the body's natural circadian rhythm, which affects white blood cell counts and bone marrow proliferation.
Researchers found that female patients with diffuse large B-cell lymphoma treated in the afternoon had reduced mortality rates and cancer recurrence compared to those treated in the morning. The study suggests that timing chemotherapy delivery according to an individual's circadian clock may improve treatment outcomes.
A new study found that the antibody-drug conjugate STRO-001 showed nanomolar cytotoxicity in 88% of cancer cell lines tested, with potent efficacy against proliferating B cells. The research supports ongoing clinical studies for patients with B-cell non-Hodgkin lymphoma.
Researchers have discovered a new biomarker that predicts the response to CAR-T cell therapy in patients with diffuse large B cell lymphoma. The biomarker identifies differentiated T cells, which can be removed from leukemia products to improve therapy success rates.
A new study analyzed tumor biopsies from patients with newly-diagnosed germinal center B cell lymphoma and found that CREBBP mutations were associated with lower disease-free survival rates. The researchers identified CLMA as a practical tool to translate experimental findings into clinical applications.
The NCCN Annual Congress on Hematologic Malignancies will address key findings on chronic lymphocytic leukemia management and CAR T-cells in diffuse large B-cell lymphoma. The event also features updates on immunotherapies in multiple myeloma treatment.
Researchers at Stanford University developed a custom molecule sBCMA-Fc V3 that inhibits the growth of both multiple myeloma and diffuse large B cell lymphoma in mice. The molecules were found to be nontoxic in monkeys, suggesting they could be used to treat humans with these deadly diseases.
A study from Weill Cornell Medicine and Cornell University reveals that targeting protein ATF4 and its related metabolic protein SIRT3 can trick lymphoma cells into starving themselves, slowing their growth.
Scientists at La Jolla Institute for Immunology have discovered a link between TET enzyme deficiency and the formation of unusual DNA structures, such as G-quadruplexes and R-loops, which contribute to genomic instability. The study suggests that regulating these structures may be key to controlling cancer development.
A new study published in the New England Journal of Medicine found that using CAR T therapy as a second-line treatment provided better outcomes compared to standard care in patients with diffuse large B-cell lymphoma. The two-year follow-up data showed a median event-free survival of 8.3 months in the CAR T arm versus 2 months in the s...
Foresight Diagnostics is presenting its proprietary PhasED-Seq technology at ICML for improved minimal residual disease (MRD) detection rates in diffuse large B-cell lymphoma (DLBCL) patients. The technology has been shown to detect relapsing disease 200 days earlier than current methods.
Researchers have developed a new chimeric antigen receptor (CAR) T cell immunotherapy that targets both CD19 and CD20 proteins, achieving complete metabolic responses in four out of five patients with relapsed or refractory B-cell lymphoma. The approach minimizes treatment resistance and prevents relapse by recognizing multiple targets.
Researchers found that a blood-clotting protein called fibrinogen promotes the clustering of cancerous B cells at sites where there is a leak in the blood-brain barrier, leading to tumor growth in the brain. Fibrinogen may be targeted as a potential treatment for central nervous system B-cell lymphoma.
A proof-of-concept study found that 68Ga-pentixafor PET imaging effectively diagnoses and manages rare CNS B-cell lymphoma by targeting the CXCR4 biomarker. The imaging modality showed excellent contrast characteristics between lymphoma lesions and surrounding healthy brain tissue.
A recent study published in Blood Advances eliminates BCL-W as a potential therapeutic target for B cell lymphomas. The research team used gene editing technology and demonstrated that human B cell lymphoma cell lines can survive without BCL-W, contradicting earlier speculation about its role in cancer survival.
A study at University of Texas M.D. Anderson Cancer Center showed a potential new approach to treating follicular lymphoma and DLBCL through manipulation of molecular programs controlled by CREBBP. Inhibition of HDAC3 restores immune programs lost as a result of CREBBP mutations, paving the way for immunotherapy approaches.
Early clinical studies with BET inhibitors and EZH2 inhibitors have shown remarkable activity in patients with lymphoma, including diffuse large B-cell lymphoma and NUT carcinoma. Tolerability has been generally good, but side effects such as thrombocytopaenia and fatigue have emerged.
Researchers at CNIC discovered that miR-28 regulates the terminal differentiation of B lymphocytes, blocking the growth of B cell lymphomas. This finding highlights the potential of synthetic miR-28 analogs to inhibit tumor growth in Burkitt lymphoma and diffuse large cell lymphoma.
The phase I trial of CAR-T therapy with axicabtagene ciloleucel resulted in a durable complete remission rate of 43% among highly refractory diffuse large B-cell lymphoma patients. The treatment showed promising clinical activity, with an overall response rate of 71%, and manageable toxicity.
Researchers have successfully combined everolimus with the standard R-CHOP regimen for new, untreated diffuse large B-cell lymphoma patients. The treatment achieved a 96% overall response rate and no dose-limiting toxicity was observed, indicating potential benefits in increasing cure rates and improving patient outcomes.
Researchers at the Max Delbrück Center for Molecular Medicine found that FOXO1 is essential for both germinal center dark zone formation and efficient B cell response to pathogens. The study sheds light on the transcription factor's role in normal immune function, but further research is needed to understand its link to lymphomagenesis.
Natural killer cells are impaired in the tumor microenvironment, but can be restored in normal conditions. Researchers identified two key factors blocking NK cell function: inflammatory cytokine IL-10 and down-regulated NKG2D ligands.
A new study found that CDK4 inhibitors may promote the development and progression of certain B-cell lymphomas driven by the MYC oncogene. Inhibiting CDK4 leads to genetic instability and genomic alterations associated with cancer growth.
Melbourne scientists found that the immune system eliminates potentially cancerous immune B cells on a daily basis. This discovery could lead to an early-warning test identifying patients at high risk of developing B-cell lymphomas.
A toxin linked to brentuximab vedotin has shown compelling antitumor activity in patients with non-Hodgkin lymphomas, including diffuse large B cell lymphoma. The study found that 40% of DLBCL patients had an objective response, with a median duration of 36 weeks.
A study found that PET/CT is more sensitive and accurate than bone marrow biopsy in detecting bone marrow involvement in DLBCL patients. The imaging modality also predicted progression-free survival and changed treatment plans for 42% of patients with bone marrow involvement.
Researchers found radioimmunotherapy using 177Lu-DOTA-rituximab to be highly effective in treating relapsing follicular, mantle cell, and other indolent B-cell lymphomas. The treatment resulted in high tumor response rates and was well-tolerated, with toxicity mainly being hematologic.
Researchers discovered a novel class of early replicating fragile sites contributing to genome instability in B cell lymphomas. These sites, uncovered through genome-wide sequencing, overlap with mutations associated with the disease and suggest a major feature of its mutational landscape.
Researchers at Northwestern University discovered a new nanoparticle that kills B-cell lymphoma cells by depriving them of natural HDL cholesterol. The nanoparticle, which mimics the size and shape of HDL particles, blocks cholesterol from entering cancer cells, leading to cell death.
Researchers at MDC Berlin-Buch identified subpopulations of B cells with activated Myc genes, essential for germinal center formation and maintenance. These findings shed light on the origin of B-cell lymphomas derived from germinal centers.
Researchers have discovered a CD19-dependent pathway that contributes to the growth of B cell lymphomas. High levels of CD19 correlate with increased MYC activity, suggesting a new target for therapies currently in clinical trials.
Researchers have discovered the FBXO11 gene as a novel tumor suppressor in B-cells, which regulates BCL6 protein levels. Deletions or mutations of FBXO11 contribute to DLBCL's development, with reconstitution of its expression inhibiting proliferation and inducing cell death.
A new study reveals that more intensive chemotherapy regimens significantly improve event-free survival and reduce mortality in younger patients with aggressive diffuse large B-cell lymphoma. Younger patients who received dose-intensive chemotherapy had an 81% event-free survival rate, compared to 67% for those on standard treatment.
Researchers at the University of Maryland School of Medicine have found a complex molecular relationship between ERK and CHK2 proteins, which could lead to new treatments for diffuse large B-cell lymphoma. The study showed that inhibiting both proteins simultaneously killed more cancer cells than treating them separately.
A modified chemotherapy regimen combining reduced CHOP doses with rituximab has shown substantial response and improved survival in very elderly patients with diffuse large B-cell lymphoma. The R-miniCHOP regimen is well-tolerated, with a high overall response rate and low treatment toxicity.
Researchers at Weill Cornell Medical College have identified a potential new combinatorial therapy for diffuse large B cell lymphoma, the most common form of non-Hodgkin lymphoma. Combining an inhibitor of BCL6 with either HDAC proteins or Hsp90 protein enhanced killing of cancer cells in vitro and suppressed tumor growth in mice.